Inorganic nanoparticles for predictive oncology of breast cancer.
Nanoparticles (NPs) and nanosized objects are being incorporated rapidly into clinical medicine and particularly into the field of medical oncology, including breast cancer. A number of novel methods for breast cancer diagnosis and treatment, which are based on NPs and other nanodevices, are now available for translation into clinical practice. Computer tomography and MRI with iron-based magnetic NPs are promising methods for radiological detection of cancers. Semiconductor fluorescent NPs (quantum dots) are being developed for simultaneous detection and localization of multiple breast cancer biomarkers, enabling the personalization of therapeutic regimens for each patient. Additionally, inorganic NPs can be conjugated with tumor-specific ligands and used for tumor-selective delivery of chemotherapeutic or hormonal agents. NPs bearing tumor-targeted antibodies and oligonucleotides for anticancer gene therapy are a novel and rapidly developing therapeutic approach in oncology. Nab-paclitaxel and liposomal anthracyclines are US FDA-approved NP-based drug-delivery systems that have demonstrated at least equivalent efficacy and decreased toxicity compared with conventional chemotherapeutic agents used in the treatment of breast cancer. This review focuses on recent applications of NPs into predictive oncology of breast cancer with an emphasis placed on the role of inorganic nanosized objects in the diagnosis and treatment of this malignancy.
Yezhelyev
Maksym
M
Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
Yacoub
Rami
R
O'Regan
Ruth
R
D000818:Animals; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D005260:Female; D006801:Humans; D007287:Inorganic Chemicals / Q000737:chemistry; D053768:Metal Nanoparticles / Q000737:chemistry; D050997:Nanomedicine / Q000379:methods; D053758:Nanoparticles / Q000737:chemistry / Q000627:therapeutic use* / Q000633:toxicity; D045663:Quantum Dots
D007287:Inorganic Chemicals